Incorporation of the structure-based IsoPSA biomarker into clinical practice

Panelists discuss how IsoPSA differs from traditional prostate-specific antigen (PSA) testing by focusing on the structure of the PSA protein rather than its concentration. This shift in measurement allows for more precise identification of clinically significant prostate cancer, reducing false-positive results and unnecessary biopsies. IsoPSA represents a significant evolution in biomarker science, emphasizing functional molecular changes instead of relying solely on serum levels.

Panelists discuss how adoption of IsoPSA in clinical practice is influenced by emerging evidence, institutional protocols, and provider awareness. Some practices have already integrated it into diagnostic workflows, particularly for patients with borderline or persistently elevated PSA levels. Others remain cautious, citing barriers such as lack of reimbursement or insufficient education about test interpretation.

Panelists discuss how broader use of IsoPSA will depend on continued validation and clinician familiarity. The panel suggests that as more providers see real-world benefits—including reduced biopsy rates and improved patient counseling—adoption will accelerate. Ultimately, IsoPSA may become a standard tool to complement imaging and other biomarkers in risk assessment strategies.